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Abstract
Venom research is a highly multidisciplinary field that involves multiple subfields of biology, informatics, pharmacology,
medicine, and other areas. These different research facets are often technologically challenging and pursued by different
teams lacking connection with each other. This lack of coordination hampers the full development of venom investigation
and applications. The COST Action CA19144–European Venom Network was recently launched to promote synergistic
interactions among different stakeholders and foster venom research at the European level.
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Background
Venomous species represent ∼15% of the global estimated ani-
mal biodiversity, are omnipresent in aquatic and terrestrial habi-
tats, and evolved independently in all metazoan lineages in >100
instances [1]. Venoms are complex mixtures of bioactive com-
pounds, mostly peptides and proteins, that evolved through mil-
lions of years of natural selection predominantly for predation
and defense. Venom toxins are adaptive and highly convergent
traits, extremely useful to understand the evolutionary mecha-
nisms that link genotype, phenotype, and protein function.
In addition, toxins are streamlined to act fast at very low
concentrations, being highly specific with key physiological tar-
gets of prey and/or predators (ion channels, enzymes, and cel-
lular membrane components) [2]. Many toxins target the neuro-
muscular system, while others possess anticoagulant, cytolytic,
anesthetic, and hypotensive activities [3]. These characteristics
make them ideal candidates for biotechnological applications.
To date, 10 animal-derived drugs have been approved and sev-
eral others are in various stages of clinical trials to treat a wide
array of diseases including cancer, hypertension, acute coronary
syndromes, and chronic pain [4]. Besides medicine, venom tox-
ins have great potential in other biotechnological fields: spider
toxins to develop eco-friendly insecticides and other agrochem-
icals [4], ion channel blockers from cone snails and bees for
cosmeceutical applications [5], and pore-forming toxins for se-
quencing and sensing technologies [6].
Venomics as a multidisciplinary playground
Venom investigation involves many scientific disciplines that
in recent years have undergone great technological improve-
ments (Fig. 1). These fast-evolving technologies foster venomics
research but also bring new challenges, necessitating consider-
able integrative expertise.
High-throughput techniques have facilitated the character-
ization of complex venoms even in non-model organisms [7].
Transcriptomic data obtained by the latest RNA-sequencing
technologies are often integrated with bottom-up proteomics,
in which high-performance liquid chromatography is coupled
with tandem mass spectrometry. This proteo-transcriptomics
approach allows the detection of low-copy transcripts and post-
translational modifications, and a precise relative quantification
of expressed proteins. Integration of genomic data is still un-
common, despite its promise for elucidating evolutionary and
regulatory patterns of venom compounds.
Bioinformatics pipelines are used for similarity-based
screening and identification of promising candidates. After-
wards, the peptide and protein toxins are synthesized via
solid-phase peptide synthesis and regioselective folding, or by
a variety of different recombinant expression systems to obtain
a realistic folding pattern. When separation and isolation of
each compound is not achievable owing to the low quantity of
raw venom, these procedures can yield amounts of proteins
suitable for subsequent activity testing, although they require
extensive optimization for each component.
Activity screening mostly relies on electrophysiology that is
applied on multiple neuroreceptors, ligand-gated and voltage-
gated ion channels involved in neurodegenerative and drug
dependency disorders, in immune system regulation, anes-
thesia, and neuropathic pain. Electrophysiology also includes
ex vivo assays and bi-dimensional array assays on tissue
preparations for neurological disorders and trauma. Other
activity screening tests target hormonal pathways, cancer,
cardiovascular or inflammatory disorders, diabetes and obe-
sity, and infectious diseases. Bioactivity-driven identification
of novel compounds is further tested by in vivo phenotypic
screens [8].
In addition, biophysical approaches such as X-ray crystallog-
raphy, nuclear magnetic resonance spectroscopy, surface plas-
mon resonance spectroscopy, isothermal titration calorimetry,
and micro-computer tomography have become key compo-
nents of drug discovery platforms and venom systems iden-
tification. In silico approaches, such as molecular modeling,







ogskolen i Innlandet user on 30 August 2021
Modica et al. 3
Figure 1: The multidisciplinary, integrative, and interconnected vision of venom research proposed in EUVEN. The centre is composed of modern morphology and
-omics methods, in particular proteomics, transcriptomics, and genomics. In the surrounding white circle, main aspects of current venom research are indicated
and summarized by the major topics in the dark grey ovals. These major topics are loosely associated with broader themes given in the light grey circle. The whole
system is affected and interacts with outer drivers (purple). This integrative scheme is the heart of EUVEN, in which 5 major Working Groups focus on these topics
and methods (top dark grey bar; see text for details). The cross subjects in which the scientific, technological, and socio-economic impact of EUVEN will be realized
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Figure 2: Number of indexed publications on venom between the years 2000 and 2020, comparing EU and extra-EU authors’ contributions to venom research. The
non-EU–authored publications doubled in the past 20 years. By contrast, the EU-only–authored ones only increased by ∼20%. The word “venom” wasted as query for
“topic.” EU and non-EU countries were then excluded to obtain publication lists of extra-EU authors only and EU authors only, respectively (Source: Web of Science,
last updated December 2020).
providing structural information and theoretical understanding
of the molecular mechanisms of toxin action [9].
The COST Action EUVEN: from fragmentation to
integration
The different facets of venomics are typically pursued by differ-
ent research groups, whose level of collaboration in the EU is
not adequate to face the increasing challenges in venomics re-
search, as reflected by the decreased relative contributions of EU
scientists to global venom research in the past 20 years (Fig. 2).
The European Venom Network COST Action CA19144 (EU-
VEN) [10] was launched in October 2020 to promote an effi-
cient exchange of ideas, knowledge, and benchmarks and to
involve all relevant stakeholders to foster European venom re-
search. The European Cooperation in Science and Technology
(COST) Association has operated since 1971 funding bottom-
up networks that run for 4 years to boost research, innovation,
and careers through a series of collaborative activities including
workshops, conferences, working group (WG) meetings, train-
ing schools, short-term scientific missions, dissemination, and
outreach.
In bringing together experts from all relevant fields, EUVEN
develops protocols on best practices in venomics and identifies
the most promising novel technological tools, animal models,
and untapped physiological targets to be integrated into current
venom research. Stronger collaborations with non-academic
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(SMEs), are enforced as a prerequisite for promoting biomedi-
cal, diagnostic, agrochemical, cosmeceutical, or nanobiotechno-
logical applications of venom compounds. EUVEN also aims to
involve non-professional societies to foster biodiversity-based
research with the support of natural history museums. Our
major research and capacity-building objectives will be tack-
led through the engagement of participants (currently from 31
countries) in 5 WGs.
WG1: Novel targets in venom research—In this WG, novel tar-
gets are established and validated to expand and diversify the
current main focus of the research community on just a few
model organisms, diseases, and molecular targets.
WG2: Best practices and innovative tools—The aim of this
WG is to validate and develop best research practices to mini-
mize variation and gather reproducible and comparable results
in all experimental and analytical steps contributing to venom
investigation. Additionally, the integration of innovative tools in
venom research will be evaluated.
WG3: Interaction with industry—The focus of WG3 is the in-
terplay between academic researchers and industrial partners
to transform researchers’ discoveries and knowledge into inno-
vations for society. EUVEN supports different initiatives to en-
courage participation of SMEs in meetings and discussions and
to increase the appeal of venom research for industries.
WG4: Web resources—Available web resources for venom re-
search currently lack a streamlined synergism. WG4 aims at in-
tegrating databases in a single repository that will also imple-
ment the most useful computational analytical tools for the de-
tection of relevant features, including folds/activities of poten-
tial applicative interest.
WG5: Training—Given the multidisciplinary nature of venom
research, EUVEN plans to offer extensive training opportunities
in all relevant venom research disciplines.
Conclusion
The new COST Action EUVEN provides a flexible platform for
scientists to overcome the lack of coordination, tools, and re-
sources, through the development of a fully synergistic network.
To guarantee the coverage of the diverse topics of interest in EU-
VEN and build an effective network across Europe and beyond,
it is fundamental to engage the broadest participation possible
from all COST participating countries. Near-neighbor and inter-
national partner countries can also request to join EUVEN and
participate in networking activities.
We believe that building an effective network that is able
to bridge different scientific disciplines and sectors constitutes
a fundamental prerequisite to fully develop the extraordinarily




COST: European Cooperation in Science and Technology; EUVEN:
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